tci Medicare Compliance & Reimbursement - 2004 Issue 36
Drug Benefit: Proposed Formulary Poses Problems For Plans, PBMs
Subscribe or sign in to view the full article.
Article Overview
This article explains how draft United States Pharmacopeia guidance for Medicare Part D drug benefit formularies may affect health plan and PBM design decisions. It covers the proposed benchmark role of the guidance, industry reactions to the number of therapeutic categories, and the broader tension between affordability, coverage breadth, and federal approval expectations. The content is relevant to health plan leaders, PBMs, formulary designers, and anyone tracking Medicare drug benefit policy.
Why This Topic Matters
The article highlights how formulary structure can influence cost control, competitive positioning, and approval expectations for Medicare drug plans. It helps readers understand the policy and operational concerns surrounding early Part D benefit design.
What You Will Learn
- What the draft USP Medicare drug benefit guidance is intended to do
- Why health plans and PBMs were concerned about the number of therapeutic categories
- How formulary breadth can affect cost management and plan design
- Why alignment with federal guidance matters for Medicare drug packages
Who Should Read This
- Health plans
- Pharmacy benefit managers
- Formulary designers
- Medicare policy analysts
- Healthcare administrators
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.


Quick, Current, Complete - www.findacode.com